Purchase this article with an account.
David Scott Hammond, Baskar Arumugam, Arthur Bradley, Myhanh Nguyen, Paul Chamberlain; Prior myopia control effects retained upon cessation of dual-focus soft contact lens wear. Invest. Ophthalmol. Vis. Sci. 2022;63(7):245 – A0099.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Quantify eye growth as a function of age, upon cessation of a dual-focus soft contact lens myopia control treatment. Are the accrued treatment effects retained independent of age?
Arumugam et al. (ARVO,2021) established models of estimated annualized axial length elongation for children fit with either MiSight 1 day (omafilcon A, dual focus, CooperVision, Inc.; M1d) or Proclear 1 day (omafilcon A, single vision, Coopervision, INC.; P1d) soft contact lenses. Following completion of a 6-year study to assess efficacy of M1d myopia control lenses, 83 subjects were refitted for one year with P1d. Axial elongation rates (mm/yr) observed after cessation of treatment were compared to previously defined age-matched model predictions for both treated and untreated myopic eyes. Annualized post-treatment measures of axial length (age range 14-18 years) were collected from children who were aged 8-12 at study inception.
Average post-treatment growth for eyes following either 6 or 3 years of treatment were below the upper 95% confidence interval of the untreated average control model growth. Post-treatment annual average elongation rates ranged between 0.15 mm/yr, 95% CI [0.11, 0.19] and 0.05 mm/yr, 95% CI [0.03,0.07] for the ages 14 to 18 years. In general, a younger age at cessation of treatment was associated with greater axial elongation rate in the following year when wearing P1d, in concordance with the untreated eye growth model. There was no evidence of a rebound effect in the 14-18 year-old age range upon cessation of M1d wear.
Post treatment return of eye growth to age normal levels reveals that accrued reductions in eye growth from myopia control with M1d were retained following treatment cessation. Data and models reveal that starting myopia control treatment with MiSight 1 day at a younger age and continuing throughout the teenage years will reduce the number of years during which untreated eye growth will occur, maximizing myopia control benefit.
This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.
This PDF is available to Subscribers Only